Secukinumab – first in class interleukin-17A inhibitor for the treatment of psoriasis
Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for rec...
Main Author: | Kiran Godse |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
Series: | Indian Journal of Dermatology |
Subjects: | |
Online Access: | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2017;volume=62;issue=2;spage=195;epage=199;aulast= |
Similar Items
-
Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study
by: Ramesh M Bhat, et al.
Published: (2017-01-01) -
Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis
by: A. V. Samtsov, et al.
Published: (2018-01-01) -
Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
by: Bruna Lavinas Sayed Picciani, et al.
Published: (2021-06-01) -
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment
by: Silvia Vidal, et al.
Published: (2021-06-01) -
Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis
by: A. A. Kubanov, et al.
Published: (2019-07-01)